跳至主要内容
临床试验/NCT02768259
NCT02768259Unknown不适用

Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue in Egyptian Patients ( Single Center Study)

Cairo University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2016年6月最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
prevalence

研究概览

简要总结

  • Measuring the incidence and prevalence of PAH in Egyptian patients with different types of MCD
  • Determination of survival & the risk factors of mortality.

详细描述

PH is defined as a mean pulmonary artery pressure greater than 25 mmHg. PAH can be assessed by different means, however right heart catheterization (RHC) is the gold standard diagnostic method .

Among the different subgroups of pulmonary arterial hypertension (PAH), those associated with connective tissue diseases (CTDs) are a specific entity with distinct hemodynamic and prognostic features reflecting the importance of a rheumatological assessment in PAH, especially with the unfavorable prognostic impact in these patients.

Compared to patients with idiopathic PAH, patients with CTD-associated PAH have a higher mortality and a lower walking distance on the 6-minute walk test, higher levels of B-type natriuretic peptide, worse right ventricular function, more left-sided heart dysfunction, lower lung function, and more pericardial disease.

That's why, PAH screening is routinely performed in systemic sclerosis (SSc) and in other CTDs and also, as suggested by international guidelines, it is important to rule out CTDs in patients with PAH, because patients diagnosed as idiopathic PAH (iPAH) may have an associated CTD previously unrecognized.

Although the similarities in pathogenesis of PAH in CTD such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and mixed connective tissue disease (MCTD), there are variabilities in outcomes in patients with CTD-associated PAH.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed as connective tissue diseases fulfilling ACR criteria will be recruited

排除标准

  • 未提供

结局指标

主要结局

prevalence

时间窗: 1 year

Pulmonary hypertension

次要结局

  • Survival(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mostafa Elshazly

Professor of pulmonary Medicine

Cairo University

研究点 (1)

Loading locations...

相似试验